effect of biejia-ruangan compound on survival rate and recurrence rate of hepatocellular carcinoma after radical treatment

Conditions: Hepatocellular Carcinoma (HCC)

Summary: this study plans to enroll 704 patients with a history of chronic hepatitis b who have undergone radical treatment for hepatocellular carcinoma. the subjects were divided into a control group (conventional treatment group) and a combination therapy group (conventional treatment plus biejia-ruangan compound) according to the doctor's clinical diagnosis and treatment and the subjects' wishes in a ratio of 1:2. the subjects in the combination therapy group were treated with biejia-ruangan compound for 72 weeks, followed by 168 weeks of follow-up, for a total study period of 240 weeks. by analyzing the 1-, 2-, 3-, and 5-year recurrence-free, overall survival rate/survival time, adverse reactions, etc., the clinical effect of biejia-ruangan compound in reducing the risk of recurrence in patients with hepatocellular carcinoma after receiving radical treatment was comprehensively evaluated, and its scientific value and practical application prospects as a potential treatment method were explored.


Eligibility criteria:
inclusion criteria: * age range: 18-75 years old (including 18 and 75 years old), regardless of gender. * individuals with chronic hepatitis b liver fibrosis or cirrhosis. * according to the "diagnosis and treatment guidelines for primary liver cancer" (2024 edition) liver cancer diagnosis roadmap, the first clinical diagnosis is hepatocellular carcinoma(hcc). * the staging of liver cancer is cnlc stage ia - iia. * radical treatment has been completed, with surgical resection or local ablation. * 8-12 weeks after radical surgery, imaging and serological evaluations showed no residual cancerous lesions and no new cancerous lesions were found. * child pugh score a/b. * voluntarily joining the group, able to understand and sign an informed consent form. exclusion criteria: * pregnant and lactating women; * prior to radical liver cancer surgery, the patient had received radiation, chemotherapy, molecular targeting, immunotherapy, and other anti-tumor treatments; * receive other anti-tumor chinese medicine (including traditional chinese patent medicines and simple preparations or chinese herbal medicine); * individuals with mental illnesses, especially those with a history of depression, anxiety, mania, schizophrenia, or a family history of mental illness (especially those with a history of depression or tendencies towards depression); * combination of hepatitis a, c, d, e, and/or current hiv infections; * kidney diseases: acute and chronic nephritis, renal insufficiency, nephrotic syndrome, etc., or screening with blood creatinine\>2.0 × uln; * autoimmune diseases, including psoriasis, systemic lupus erythematosus, autoimmune liver disease, etc; * patients who experience upper gastrointestinal bleeding within the first 3 months (including the screening period) prior to screening; * individuals with a serious history of heart disease, especially those with unstable or poorly controlled heart disease within the past 6 months; * individuals who plan to receive organ transplantation or have already undergone organ transplantation; * those who are allergic to compound biejia ruangan tablets, nucleoside (acid) analogues, or drug excipients, or who meet any contraindications in the experimental drug instructions; * have used other anti fibrotic drugs within the first 6 months of enrollment, such as fuzheng huayu, anluo huaxian, and ganshuang granules. * other situations where the participant has participated in other intervention trials within the previous month or where the researcher deems it unsuitable for inclusion.